Ievgeniia Merenkova

Dr. Ievgeniia Merenkova

SI “National institute of phthisiology and pulmonology named after F.G. Yanovsky NAMS of Ukraine”
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
Volodymyr GavrysyukVolodymyr Gavrysyuk
Volodymyr Gavrysyuk
IMIevgeniia Merenkova
Ievgeniia Merenkova
YDYaroslav Dziublyk
Yaroslav Dziublyk
NMNataliia Morska
Nataliia Morska
NPNataliia Pendalchuk
Nataliia Pendalchuk
NVNataliia Vlasova
Nataliia Vlasova
Background: There is insufficient information in the literature on the comparative efficacy and tolerability of methotrexate (MTX) and methylprednisolone (MP) in patients with pulmonary sarcoidosis in assessing primary outcomes and the relapse rate. Purpose: The aim of our study was to evaluate primary and long-term outcomes of using MTX and MP in patients with pulmonary sarcoidosis. Methods: A total of 143 patients with newly diagnosed pulmonary sarcoidosis, verified by high-resolution computed tomography (CT) data, were examined. Corticosteroid (CS) therapy was used in 97 patients using MP at a dose of 0.4 mg/kg body weight for 4 weeks, followed by a dose reduction to 0.1 mg/kg by the end of the sixth month. The total duration of CS therapy was 12 months on average. Forty-six patients were treated with MTX at a dose of 10 mg/week (28) and 15 mg/week (18) per os for 6 to 12 months. The study of the relapse rate was conducted within 12 months after the CT data normalization in 60 patients after CS therapy and in 24 after MTX treatment. Results: MP treatment was successfully completed in 68 (70.1%), and MTX in 29 (60.4%) patients. In five MP patients (5.2%) and in five (10.9%) MTX, treatment was discontinued due to serious side effects. In seven (7.2%) MP patients and ten (21.7%) MTX patients, treatment required additional therapy due to the lack of efficacy. Progression with MP treatment (17–17.5%) was more common than with MTX (2–4.3%; Chi square = 4.703, p = 0.031). Relapses after MP therapy were observed in 26 (43.3%) patients, and after MTX therapy in 2 (8.3%; Chi square = 9.450, p = 0.003). Conclusion: In patients with pulmonary sarcoidosis, MTX monotherapy does not differ significantly from MP monotherapy in terms of the level of efficacy and the rate of serious side effects. Increasing the MTX dose from 10 to 15 mg/week accelerates the rate of regression of sarcoidosis, improves treatment efficacy, and does not affect the rate of serious side effects. When using MTX, there is a significant decrease in the incidence of treatment resistance and the relapse rate.

9 September 2023 in European Respiratory Journal
Verified
Conference Paper
Closed access
IMIevgeniia Merenkova
Ievgeniia Merenkova
VGVolodymyr Gavrysyuk
Volodymyr Gavrysyuk
YDYaroslav Dziublyk
Yaroslav Dziublyk
GGGalyna Gumeniuk
Galyna Gumeniuk
There is no generally accepted definition of refractory sarcoidosis. Considering the opinion of world leading experts and our own experience we can offer the following definition - the variant of sarcoidosis, when systemic glucocorticosteroids (GCS) in maintenance dose of ≥ 10 mg daily (prednisolone equivalent) and methotrexate (MTX) alone or in combination are not effective enough to achieve clinical remission. Aim: to evaluate retrospectively the prevalence of refractory pulmonary sarcoidosis. Methods: We examined 250 patients with sarcoidosis – 106 men (42,4 %), and 144 women (57,6 %), mean age 44 years, radiological stage II – 237 (94,8 %), stage 3 – 13 (5,2 %). GCS therapy using methylprednisolone (MP) was initiated in 190 patients with starting dose of 0,4 mg/kg for 4 weeks, following the tapering of the dose down to 0,1 mg/kg by the end of 6th month. MTX as monotherapy (15 mg once per week) was administered to 60 patients with contraindications to GCS or serious adverse reactions on MP. In case of progression of the disease or lack of response, a combination therapy was used: MP 12 mg daily and MTX 10 mg once a week. In patients with progression or stabilization of the disease after being on this therapy for at least 6 months, we considered as refractory sarcoidosis. Results: Resistance to GCS therapy (progression or stabilization on the background of treatment) was registered in 55 (28,9 %) patients. Treatment failure among patients taking MTX was observed less often (7 patients – 11,7 %). Refractory pulmonary sarcoidosis was observed in 27 (10,8 %) of patients. Conclusion: Prevalence of refractory pulmonary sarcoidosis in Ukraine is 10,8 %.

1 April 2021
Verified
Journal Article
Closed access
VGV Gavrysyuk
V Gavrysyuk
IMIevgeniia Merenkova
Ievgeniia Merenkova
NVN Vlasova
N Vlasova
OBO Bychenko
O Bychenko

30 March 2018 in EUREKA: Health Sciences
Verified
Journal Article
Open access
PDF file
VGVolodymyr Gavrysiuk
Volodymyr Gavrysiuk
IMIevgeniia Merenkova
Ievgeniia Merenkova
GGGalyna Gumeniuk
Galyna Gumeniuk
Patients who have contraindications to the prescription of GCs (glucocorticosteroids), or have developed serious side effects during treatment with GCs, as well as patients with resistance to GCs therapy, are prescribed immunosuppressants. The aim of the research - to study the efficacy of leflunomide monotherapy in patients with pulmonary sarcoidosis with contraindications to prescription or serious side effects of glucocorticosteroids. Fourteen patients with sarcoidosis of the respiratory system of stage II were examined – 12 women and 2 men aged 30 to 69 years. In 10 patients there were contraindications to the appointment of GCs (diabetes mellitus – 5, hypertension – 3, obesity – 1, exacerbation of gastric ulcer – 1), which caused the appointment of immunosuppressive therapy as a starting. In 4 cases, serious side effects of SCs were noted, requiring the drug to be abolished (osteoporosis – 3, steroid diabetes – 1). Leflunomide was administered at a dose of 20 mg per day, daily for 3 months. The evaluation of efficacy was carried out using computed tomography of the thoracic cavity organs, body plethysmography, spirometry and determination of the diffusivity of the lungs. Monotherapy with leflunomide in patients with contraindications to prescription or serious side effects of GCs was successful in 7 out of 13 patients, in 2 patients there was a stabilization of the process, in 4 patients with leflunomide therapy progression of the disease was noted and in 1 case the treatment was discontinued due to serious side effects of preparation. The results obtained make it possible to recommend the use of leflunomide as monotherapy in patients with pulmonary sarcoidosis with contraindications to the prescription and/or poor tolerability of GCs and methotrexate. It is necessary to continue studying the possibilities of combined use of leflunomide with other drugs of the first line.

5 September 2021 in European Respiratory Journal
Verified
Conference Paper
Closed access
IMIevgeniia Merenkova
Ievgeniia Merenkova
VGVolodymyr Gavrysyuk
Volodymyr Gavrysyuk
YDYaroslav Dziublyk
Yaroslav Dziublyk
GGGalyna Gumeniuk
Galyna Gumeniuk
Bone marrow suppression, associated with more frequent and probably more severe infections, is one of the most prevalent adverse reaction of methotrexate. Aim: to study the effect of methotrexate therapy on the course of COVID-19 in pulmonary sarcoidosis patients. Methods: 27 patients with pulmonary sarcoidosis (12 men and 15 women, 25­–70 years of age), receiving methotrexate, were under our supervision. All patients received methotrexate 15 mg once per week. All patients were examined using clinical methods and chest computed tomography (CT). The questionnaire queried whether patients had been infected with COVID-19 and outcome of the infection. Results: During the study period (beginning from January 2020 till January 2021) 6 patients were diagnosed with COVID-19. Obesity was the main reason for methotreaxate use in all these patients. The course of disease was mild and not requiring hospitalization in 5 patients. Severe course of COVID-19 was registered in 1 patient. She was diagnosed with bilateral polysegmental viral pneumonia with the extent of involvement of about 75 % of lung parenchyma. The patient was admitted to the hospital and methotrexate was temporary discontinued. The initiated therapy was effective and led to a relief of dyspnea, improved general condition and partial resolution of lung lesions, found on CT. More severe course of COVID-19 could also be explained by the presence of concomitant diabetes mellitus. Conclusion: Use of methotrexate for the treatment of sarcoidosis had no impact on the course of COVID-19.

6 November 2026 in Tuberculosis, Lung Diseases, HIV Infection
Verified
Journal Article
Open access
PDF file
Volodymyr GavrysyukVolodymyr Gavrysyuk
Volodymyr Gavrysyuk
IMIevgeniia Merenkova
Ievgeniia Merenkova
YDYaroslav Dziublyk
Yaroslav Dziublyk
GGG.L. Gumeniuk
G.L. Gumeniuk
MGM.I. Gumeniuk
M.I. Gumeniuk
In 2021, the ERS Official Document «Clinical practice guidelines on the treatment of sarcoidosis» was published, which defined new approaches to the treatment of patients with sarcoidosis, revised the concept of «clinical remission», which was based primarily normalisation of computed tomography (CT) findings. Quality of life (QoL) indicators are recommended as the primary point of evaluation of treatment effective­ness. The Fatigue Assessment Scale (FAS) and King’s Sarcoidosis Questionnaire (KSQ), specific for sarcoidosis, have been developed. At the same time, there is a lack of data in the literature on the dependence of QoL indicators on radiological findings and parameters of lung function. Objective — to investigate the correlation between FAS, KSQ and spirometry, the structure of total lung capacity and diffusion capacity, and CT findings. Materials and methods. The study included 32 patients with stage II pulmonary sarcoidosis: 16 with newly diagnosed and 16 with relapsed in the active phase of relapse. Patients were examined by high-resolution CT using a scoring system for CT signs. Lung function was assessed by spirometry, examination of the structure of the total capacity, and lung diffusion capacity. The Spearman’s rank correlation method was used to study the relationships between FAS and KSQ scores and other parameters. The strength of the relationships was assessed using the Chaddock scale. Results and discussion. The strongest correlation was observed between FAS values and the degree of lesion site and density of micronodular granuloma clusters. The correlation between FAS and spirometry was very weak. The results are consistent with the literature on the importance of systemic granulomatous inflammation with the release of proinflammatory cytokines in the mechanisms of fatigue development. The relationships between the Lungs module of the KSQ, which assesses respiratory symptoms, and lung function as well as CT scan findings were expectedly opposite. The results emphasise that a reliable QoL assessment can be obtained only with the integrated use of two complementary instruments — FAS and KSQ. Conclusions. The results of the study of the correlation between FAS, KSQ and spirometry, the structure of total lung capacity and diffusion capacity, CT findings, give reason to recommend the quality of life assessment tools as useful supplementary indicators for determining the timing of the start of specific therapy, correction of its regimens and the timing of the end of treatment in patients with pulmonary sarcoidosis.